

Full Title

Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years (MARiT)

General summary

The MARiT trial was a prospective, multicenter, phase II clinical trial to determine the efficacy and safety of induction therapy with rituximab and HD Ara-C every three weeks for 6 cycles, followed by BEAM and autologous stem cell rescue as primary treatment in patients under 66 years with mantle cell lymphoma.

Publication of clinical trial results

The data from the first five patients was reviewed and despite none of these patients being classified as MIPI (standard) high risk mantle cell lymphoma patients, the induction treatment, using the anti-metabolite Ara-C, rituximab and dexamethasone, failed to induce sufficient responses. The stopping rules for this study included two out of 10 patients failed to respond to the induction treatment the study would be stopped. Therefore, the trial was terminated early due to lack of efficacy in the first five patients and thus there is no result-related data to report.

EudraCT number:	2011-004039-30
Sponsor:	University Hospitals Plymouth NHS Trust (formerly Plymouth Hospitals NHS Trust)
Sponsor address:	Research Office, University Hospitals Plymouth NHS Trust, Level 2 MSCP, Bircham Park Offices, 1 Roscoff Rise, Derriford, Plymouth PL6 5FP, UK
Chief Investigator:	Professor Simon Rule
Scientific contact:	Professor Simon Rule, Consultant Haematologist Haematology Department, Derriford Hospital, Plymouth PL6 8DH, UK Email: simon.rule@nhs.net
Public contact:	Dr Chris Rollinson, Research Governance Manager Research Office, University Hospitals Plymouth NHS Trust, Level 2 MSCP, Bircham Park Offices, 1 Roscoff Rise, Derriford, Plymouth PL6 5FP, UK Email: crollinson@nhs.net